<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Linagliptin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08882</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Linagliptin is a <span class="caps">DPP</span>-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [Wikipedia]. Two pharmacological characteristics that sets linagliptin apart from other <span class="caps">DPP</span>-4 inhibitors is that it has a non-linear pharmacokinetic profile and is not primarily eliminated by the renal system. <span class="caps">FDA</span> approved on May 2, 2011.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB08882/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB08882/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08882.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08882.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08882.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08882.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08882.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB08882">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>BI-1356</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Trajenta</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Tradjenta</td><td>Boehringer Ingelheim</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Jentadueto</td><td>Linagliptin and metformin hydrochloride</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/dipeptidyl-peptidase-iv-inhibitors">Dipeptidyl-Peptidase IV Inhibitors</a></li>
<li><a href="/mesh/antidiabetic-agents">Antidiabetic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>668270-12-0</td></tr><tr><th>Weight</th><td>Average: 472.5422<br>Monoisotopic: 472.23352218</td></tr><tr><th>Chemical Formula</th><td>C<sub>25</sub>H<sub>28</sub>N<sub>8</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>LTXREWYXXSTFRX-QGZVFWFLSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-2,3,6,7-tetrahydro-1H-purine-2,6-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Imidazopyrimidines</td></tr><tr><th>Subclass</th><td>Purines and Purine Derivatives</td></tr><tr><th>Direct parent</th><td>Xanthines</td></tr><tr><th>Alternative parents</th><td>Purinones; Quinazolines; Aminopiperidines; Pyrimidones; Benzene and Substituted Derivatives; N-substituted Imidazoles; Tertiary Amines; Polyamines; Monoalkylamines</td></tr><tr><th>Substituents</th><td>3-aminopiperidine; pyrimidone; pyrimidine; piperidine; benzene; n-substituted imidazole; imidazole; azole; tertiary amine; polyamine; primary amine; amine; primary aliphatic amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Linagliptin is used for the management of type 2 diabetes mellitus. </td></tr><tr><th>Pharmacodynamics</th><td>Linagliptin is a more potent inhibitor of DPP-4 than other drugs that belong to the same class with an IC50 of 1 nM. In comparison, sitagliptin, saxagliptin, and vildagliptin have an IC50 of 19, 50, and 62 nM respectively. A dose of 2.5 and 5 mg reduces the activity of DPP-4 by 72.7% and 86.1% from baseline respectively in healthy male subjects. In diabetes patients, a dose of 5 and 10 mg inhibits &gt;90% of DPP-4. Linagliptin is also selectively inhibits DPP-4 as indicated by the lack of DPP-8 or DPP-9 inhibition at therapeutic exposures in vitro. </td></tr><tr><th>Mechanism of action</th><td>Linagliptin is a competitive and reversible dipeptidyl peptidase (DPP)-4 enzyme inhibitor that slows the breakdown of insulinotropic hormone glucagon-like peptide (GLP)-1 for better glycemic control in diabetes patients. GLP and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones that increase the production and release of insulin from pancreatic beta cells and decrease the release of glucagon from pancreatic alpha cells. This results in a overall decrease in glucose production in the liver and increase an of insulin in a glucose-dependent manner.</td></tr><tr><th>Absorption</th><td>Cmax, 5 mg, healthy subjects = 8.32 nmol/L; 
Tmax, 5 mg, healthy subjects = 1.75 hours;
AUC(0-24 hours), 5 mg, healthy subjects = 119 nmol &#183; h/L;
Bioavailability, healthy subjects = 30%. 
When a dose of 5 mg once daily is given, steady state is achieved by the third dose. Although a high fat meal reduces Cmax and increases AUC, this interaction with food is not clinically significant. Linagliptin may be administered with or without food. </td></tr><tr><th>Volume of distribution</th><td><p>Vd = 1110 L</p></td></tr><tr><th>Protein binding</th><td>70-80% protein bound, the extent to which is concentration dependent. Because of the propensity of linagliptin to bind to plasma protein, it has a long terminal half-life and a non-linear pharmacokinetic profile. In contrast, other DPP-4 inhibitors have linear pharmacokinetic profiles which makes linagliptin unique. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Linagliptin is not extensively metabolized, 90% of dose is excreted unchanged. The small portion of drug that is metabolized, the main metabolite is CD 1790 and is pharmacologically inactive. Glucuronidation forms some of its other minor metabolites. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Linagliptin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00811">CD 1790</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/832">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Linagliptin is eliminated via the feces/enteroheptic system (80%) and urine (5%). This is unlike other DPP-4 inhibitors which are primarily eliminated by the renal system. </td></tr><tr><th>Half life</th><td>Terminal half life = 131 hours. Because of this long half-life, inhibition of DPP-4 activity is sustained which indicates that once-daily dosing is appropriate. Effective half-life for accumulation of drug is 12 hours when multiple oral doses of 5 mg are given. </td></tr><tr><th>Clearance</th><td><p>Renal clearance, steady state = 70 mL/min</p></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9513</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5842</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.774</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5185</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7716</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6658</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.803</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7335</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7013</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9273</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8474</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9176</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8163</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5548</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8562</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5444
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8587
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9966
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7553 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.6109
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8116
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>5 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>CYP3A4 and p-glycoprotein inducers may decreases levels of linagliptin. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Linagliptin, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy if possible, and to monitor linagliptin therapy if concurrent use cannot be avoided.</td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>CYP3A4 inducers may decrease levels of linagliptin and diminish the hypoglycemic effect of antidiabetic agents. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>CYP3A4 inducers may decrease levels of linagliptin and diminish the hypoglycemic effect of antidiabetic agents. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>CYP3A4 and p-glycoprotein inducers may decreases levels of linagliptin. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>CYP3A4 inhibitors may increase levels of linagliptin. Monitor concomitant therapy closely. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Although a high fat meal reduces Cmax and increases AUC, this interaction with food is not clinically significant</li></ul></td></tr></tbody></table>